Selected research
Market Structure
Global Haemophilus b Conjugate Vaccine (Hib) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Haemophilus b Conjugate Vaccine (Hib) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Haemophilus b Conjugate Vaccine (Hib) include Merck, GSK and Sanofi Pasteur, SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Haemophilus b Conjugate Vaccine (Hib) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Haemophilus b Conjugate Vaccine (Hib) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Haemophilus b Conjugate Vaccine (Hib) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Haemophilus b Conjugate Vaccine (Hib) market size, projected growth trends, production technologies, key applications, and end-use industries.
Haemophilus b Conjugate Vaccine (Hib) Segment by Company
Merck
GSK
Sanofi Pasteur, SA
Haemophilus b Conjugate Vaccine (Hib) Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Haemophilus b Conjugate Vaccine (Hib) Segment by Application
Government Institution
Private Sector
Other
Haemophilus b Conjugate Vaccine (Hib) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilus b Conjugate Vaccine (Hib) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Haemophilus b Conjugate Vaccine (Hib) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilus b Conjugate Vaccine (Hib).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Haemophilus b Conjugate Vaccine (Hib) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Haemophilus b Conjugate Vaccine (Hib) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Haemophilus b Conjugate Vaccine (Hib) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Haemophilus b Conjugate Vaccine (Hib) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccine
- Live Attenuated Vaccine
Applications
- Government Institution
- Private Sector
- Other
Companies covered
- Merck
- GSK
- Sanofi Pasteur, SA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Haemophilus b Conjugate Vaccine (Hib) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Haemophilus b Conjugate Vaccine (Hib) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Haemophilus b Conjugate Vaccine (Hib) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Haemophilus b Conjugate Vaccine (Hib) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Haemophilus b Conjugate Vaccine (Hib) Market Dynamics
- 2.1 Haemophilus b Conjugate Vaccine (Hib) Industry Trends
- 2.2 Haemophilus b Conjugate Vaccine (Hib) Industry Drivers
- 2.3 Haemophilus b Conjugate Vaccine (Hib) Industry Opportunities and Challenges
- 2.4 Haemophilus b Conjugate Vaccine (Hib) Industry Restraints
3 Haemophilus b Conjugate Vaccine (Hib) Market by Manufacturers
- 3.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Manufacturers (2021-2026)
- 3.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Manufacturers (2021-2026)
- 3.3 Global Haemophilus b Conjugate Vaccine (Hib) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Haemophilus b Conjugate Vaccine (Hib) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Haemophilus b Conjugate Vaccine (Hib) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Haemophilus b Conjugate Vaccine (Hib) Manufacturers, Product Type & Application
- 3.7 Global Haemophilus b Conjugate Vaccine (Hib) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Haemophilus b Conjugate Vaccine (Hib) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Haemophilus b Conjugate Vaccine (Hib) Players Market Share by Revenue in 2025
- 3.8.3 2025 Haemophilus b Conjugate Vaccine (Hib) Tier 1, Tier 2, and Tier 3
4 Haemophilus b Conjugate Vaccine (Hib) Market by Type
- 4.1 Haemophilus b Conjugate Vaccine (Hib) Type Introduction
- 4.1.1 Inactivated Vaccine
- 4.1.2 Live Attenuated Vaccine
- 4.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type
- 4.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2021-2032)
- 4.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2021-2032)
- 4.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type
- 4.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2021-2032)
- 4.3.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2021-2032)
5 Haemophilus b Conjugate Vaccine (Hib) Market by Application
- 5.1 Haemophilus b Conjugate Vaccine (Hib) Application Introduction
- 5.1.1 Government Institution
- 5.1.2 Private Sector
- 5.1.3 Other
- 5.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application
- 5.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2021-2032)
- 5.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2021-2032)
- 5.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application
- 5.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2021-2032)
- 5.3.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2021-2032)
6 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region
- 6.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2021-2032)
- 6.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2021-2026)
- 6.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Haemophilus b Conjugate Vaccine (Hib) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Haemophilus b Conjugate Vaccine (Hib) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region
- 7.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region
- 7.1.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2021-2026)
- 7.1.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2027-2032)
- 7.1.4 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Haemophilus b Conjugate Vaccine (Hib) Revenue (2021-2032)
- 7.2.2 North America Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Haemophilus b Conjugate Vaccine (Hib) Revenue (2021-2032)
- 7.3.2 Europe Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Merck Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 GSK
- 8.2.1 GSK Company Information
- 8.2.2 GSK Business Overview
- 8.2.3 GSK Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 GSK Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
- 8.2.5 GSK Recent Developments
- 8.3 Sanofi Pasteur, SA
- 8.3.1 Sanofi Pasteur, SA Company Information
- 8.3.2 Sanofi Pasteur, SA Business Overview
- 8.3.3 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
- 8.3.5 Sanofi Pasteur, SA Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Haemophilus b Conjugate Vaccine (Hib) Value Chain Analysis
- 9.1.1 Haemophilus b Conjugate Vaccine (Hib) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Haemophilus b Conjugate Vaccine (Hib) Production Mode & Process
- 9.2 Haemophilus b Conjugate Vaccine (Hib) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Haemophilus b Conjugate Vaccine (Hib) Distributors
- 9.2.3 Haemophilus b Conjugate Vaccine (Hib) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst